Fate Therapeutics Q3 2026 net loss narrows year over year to $30.69 million
Bitget2026/11/05 12:18- Fate Therapeutics’ third-quarter 2026 net loss narrowed year over year to $30.69 million.
- There was no collaboration revenue, while operating expenses fell 12% year over year to $32.25 million.
- Cash, cash equivalents and investments totaled $139.1 million at September 30; cash runway is expected to extend to mid-2028.
- The potentially registrational RECLAIM-LN trial in lupus nephritis opened enrollment across 17 active sites.
- FT839’s Phase 1/2 autoimmune trial activated multiple clinical sites, with patient dosing expected by year-end 2026.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Jensen Huang's influence surpasses that of Nvidia— and that's exactly the problem
Jensen Huang has been the key driving force behind the massive expansion of AI infrastructure, with his personal credibility and authoritative decision-making deeply embedded in the narrative of the global tech market’s rise over the past three years. Now, as scandals emerge, Nvidia’s trading team is expected to become more conservative and slow down external financing commitments, which undoubtedly worsens the situation for neoclouds already facing tight funding.
Deutsche Bank made significant Q3 purchases of midstream AI application stocks: the three major cloud giants saw increased holdings, with Palantir (PLTR.US) and Salesforce (CRM.US) also favored.
Deutsche Bank has submitted its third quarter 13F holdings report for the period ending September 30, 2026.
Crypto prices
More
